334 related articles for article (PubMed ID: 23774906)
1. Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm.
Robertson J; Peters MJ; McInnes IB; Sattar N
Nat Rev Rheumatol; 2013 Sep; 9(9):513-23. PubMed ID: 23774906
[TBL] [Abstract][Full Text] [Related]
2. Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy.
Curtis JR; John A; Baser O
Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1282-91. PubMed ID: 22504829
[TBL] [Abstract][Full Text] [Related]
3. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease.
Myasoedova E; Crowson CS; Kremers HM; Roger VL; Fitz-Gibbon PD; Therneau TM; Gabriel SE
Ann Rheum Dis; 2011 Mar; 70(3):482-7. PubMed ID: 21216812
[TBL] [Abstract][Full Text] [Related]
4. Lipid management in rheumatoid arthritis: a position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology.
Hollan I; Ronda N; Dessein P; Agewall S; Karpouzas G; Tamargo J; Niessner A; Savarese G; Rosano G; Kaski JC; Wassmann S; Meroni PL
Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):104-114. PubMed ID: 31397840
[TBL] [Abstract][Full Text] [Related]
5. Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis.
Naerr GW; Rein P; Saely CH; Drexel H
Vascul Pharmacol; 2016 Jun; 81():22-30. PubMed ID: 26903239
[TBL] [Abstract][Full Text] [Related]
6. Are lipid ratios less susceptible to change with systemic inflammation than individual lipid components in patients with rheumatoid arthritis?
Toms TE; Panoulas VF; Douglas KM; Nightingale P; Smith JP; Griffiths H; Sattar N; Symmons DP; Kitas GD
Angiology; 2011 Feb; 62(2):167-75. PubMed ID: 20682616
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular Risk Assessment and Therapeutic Implications in Rheumatoid Arthritis.
Halacoglu J; Shea LA
J Cardiovasc Transl Res; 2020 Oct; 13(5):878-890. PubMed ID: 32080804
[TBL] [Abstract][Full Text] [Related]
8. Increased lipid levels but unchanged atherogenic index in rheumatoid arthritis patients treated with biologic disease modifying antirheumatic drugs: published experience.
Schimmel EK; Yazici Y
Clin Exp Rheumatol; 2009; 27(3):446-51. PubMed ID: 19604437
[TBL] [Abstract][Full Text] [Related]
9. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions.
Choy E; Sattar N
Ann Rheum Dis; 2009 Apr; 68(4):460-9. PubMed ID: 19286905
[TBL] [Abstract][Full Text] [Related]
10. Lipid paradox in rheumatoid arthritis: changes with rheumatoid arthritis therapies.
Amezaga Urruela M; Suarez-Almazor ME
Curr Rheumatol Rep; 2012 Oct; 14(5):428-37. PubMed ID: 22802154
[TBL] [Abstract][Full Text] [Related]
11. Lipids and lipid changes with synthetic and biologic disease-modifying antirheumatic drug therapy in rheumatoid arthritis: implications for cardiovascular risk.
Myasoedova E
Curr Opin Rheumatol; 2017 May; 29(3):277-284. PubMed ID: 28207495
[TBL] [Abstract][Full Text] [Related]
12. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis.
Gabay C; McInnes IB; Kavanaugh A; Tuckwell K; Klearman M; Pulley J; Sattar N
Ann Rheum Dis; 2016 Oct; 75(10):1806-12. PubMed ID: 26613768
[TBL] [Abstract][Full Text] [Related]
13. Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist.
Charles-Schoeman C; Gonzalez-Gay MA; Kaplan I; Boy M; Geier J; Luo Z; Zuckerman A; Riese R
Semin Arthritis Rheum; 2016 Aug; 46(1):71-80. PubMed ID: 27079757
[TBL] [Abstract][Full Text] [Related]
14. Conventional lipid profile and lipoprotein(a) concentrations in treated patients with rheumatoid arthritis.
García-Gómez C; Nolla JM; Valverde J; Gómez-Gerique JA; Castro MJ; Pintó X
J Rheumatol; 2009 Jul; 36(7):1365-70. PubMed ID: 19369465
[TBL] [Abstract][Full Text] [Related]
15. Lipids in RA: Is Less Not Necessarily More?
Plutzky J; Liao KP
Curr Rheumatol Rep; 2018 Feb; 20(2):8. PubMed ID: 29464513
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment.
Choy E; Ganeshalingam K; Semb AG; Szekanecz Z; Nurmohamed M
Rheumatology (Oxford); 2014 Dec; 53(12):2143-54. PubMed ID: 24907149
[TBL] [Abstract][Full Text] [Related]
17. Management of dyslipidaemia in high-risk patients with recent-onset rheumatoid arthritis: targets still not met despite specific recommendations. Results from the ESPOIR cohort during the first five years of follow-up.
Tournadre A; Pereira B; Dubost JJ; Rincheval N; Rat AC; Combe B; Soubrier M
Clin Exp Rheumatol; 2017; 35(2):296-302. PubMed ID: 28079508
[TBL] [Abstract][Full Text] [Related]
18. High density lipoprotein in rheumatoid arthritis: emerging role in predicting inflammation level and osteoporosis occurrence.
Zeng T; Tan L; Yu J; Wu Y
Scand J Clin Lab Invest; 2020 Sep; 80(5):375-380. PubMed ID: 32279574
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of lipid phenotypes, serum lipid behaviour over follow-up and predictors of serum lipid levels in a cohort of Mexican Mestizo early rheumatoid arthritis patients treated with conventional disease-modifying anti-rheumatic drugs.
Sánchez T; Contreras-Yáñez I; Elías-López D; Aguilar Salinas CA; Pascual-Ramos V
Clin Exp Rheumatol; 2014; 32(4):509-15. PubMed ID: 25005131
[TBL] [Abstract][Full Text] [Related]
20. Atherogenic lipid profiles and its management in patients with rheumatoid arthritis.
Nurmohamed MT
Vasc Health Risk Manag; 2007; 3(6):845-52. PubMed ID: 18200805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
